Pfizer vs Moderna
Pfizer parlayed its pandemic windfall into a massive acquisition spree, while Moderna is still running hard to diversify beyond its mRNA COVID franchise before the revenue cliff steepens. Both companies stake their futures on pipeline execution in a business where clinical failure can erase billions of market cap overnight. Pfizer vs Moderna forces you to weigh an established diversified pharma engine against a pure-play mRNA bet.
Pfizer parlayed its pandemic windfall into a massive acquisition spree, while Moderna is still running hard to diversify beyond its mRNA COVID franchise before the revenue cliff steepens. Both compani...
Why It's Moving
Pfizer Analysts Cluster Around $28 Target Amid Mixed Buy-Hold Signals for 2026
- RBC Capital's April 20 note set a $25 target, signaling downside risks tied to slower-than-expected oncology growth.
- Consensus from 24-36 analysts leans toward neutral-to-buy with average targets of $28-$30, driven by steady dividend appeal and cost-cutting momentum.
- High-end forecasts hit $36-$38, betting on blockbuster potential from new vaccines and rare disease therapies.
Pfizer Analysts Cluster Around $28 Target Amid Mixed Buy-Hold Signals for 2026
- RBC Capital's April 20 note set a $25 target, signaling downside risks tied to slower-than-expected oncology growth.
- Consensus from 24-36 analysts leans toward neutral-to-buy with average targets of $28-$30, driven by steady dividend appeal and cost-cutting momentum.
- High-end forecasts hit $36-$38, betting on blockbuster potential from new vaccines and rare disease therapies.
Investment Analysis
Pfizer
PFE
Pros
- Pfizer maintains a wide economic moat from its established drug portfolio and brand strength.
- Pfizer offers a high dividend yield of around 6.74% to shareholders.
- Pfizer exhibits low stock volatility of approximately 5.6%, reducing price fluctuation risk.
Considerations
- Pfizer anticipates a 23% decline in its COVID-19 business, pressuring 2026 revenues.
- Pfizer faces a looming patent cliff on key best-selling drugs, risking revenue losses.
- Pfizer trimmed its FY2026 profit forecast to $2.80-$3 per share, below analyst estimates.
Moderna
MRNA
Pros
- Moderna projects 10% revenue growth for 2026, driven by pipeline advancements.
- Moderna holds a healthy current ratio of 3.93, ensuring strong liquidity coverage.
- Moderna anticipates key 2026 catalysts from its Phase III melanoma trial readout.
Considerations
- Moderna reports high stock volatility of nearly 20%, increasing investment risk.
- Moderna experienced a 56% revenue decline over the last twelve months with negative EBITDA.
- Moderna shows a negative gross profit margin of -107.62%, indicating ongoing unprofitability.
Pfizer (PFE) Next Earnings Date
Pfizer's next earnings date is scheduled for May 5, 2026, before the market opens, covering Q1 2026 results. This follows the pattern of their prior Q4 2025 report on February 3, 2026. Investors should monitor for the conference call details around 10:00 AM ET.
Pfizer (PFE) Next Earnings Date
Pfizer's next earnings date is scheduled for May 5, 2026, before the market opens, covering Q1 2026 results. This follows the pattern of their prior Q4 2025 report on February 3, 2026. Investors should monitor for the conference call details around 10:00 AM ET.
Buy PFE or MRNA in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
